Jacob S. Aday, Ph.D. is a Research Assistant Professor in the Chronic Pain and Fatigue Research Center as well as the Michigan Psychedelic Center at the University of Michigan. His research interests are focused on studying the clinical applications of psychedelics, improving research methodology and safety with the drugs, and evaluating their potential use for chronic pain populations.

Julia earned her PhD at the Centre for Psychedelic Research at Imperial College London. With a background in neuroscience, she has been involved in several psychedelic trials at Imperial. Her research is focused on investigating the therapeutic potential of treating Chronic Pain conditions with psychedelic substances. She and her team at Imperial recently completed a study on psilocybin for the treatment of Fibromyalgia to stunning result. Special interests include embodiment, mindfulness, compassion, movement, and public involvement in research.

Managing Owner of Unwind Oakland and Unwind Learning, and author of the forthcoming book Beginner’s Body: Introduction to Ketamine-Assisted Therapeutic Massage and Bodywork. Suz published the first NCBTMB approved continuing ethics education course for massage therapists on psychedelics and entheogens: Introduction to Psychedelic Conversations and the Massage Table. She teaches workshops such as Ethical Safety and Support Touch for Guides, Traditional Healers, Psychotherapists, and With-nesses in multiple languages and cross-cultural groups, and produced the Touch with Substance Conference in 2024. 

Holistic physical therapist and natural medicine facilitator based in Denver, Colorado where she helps adults with chronic pain and other persistent symptoms restore movement and resilience. Marin blends physical therapy, myofascial release, yoga, breathwork, and somatic practices with a collaborative approach. Marin founded Coherence Health, a natural medicine facilitation, preparation, and integration practice. As a licensed Natural Medicine Facilitator under Colorado’s regulatory framework, Marin offers somatically-oriented psychedelic-assisted care, supporting clients to safely explore expanded states as a catalyst for body-based healing.

Joel Castellanos, MD, is a board-certified physical medicine and rehabilitation and pain medicine physician, and serves as medical director of Inpatient Rehabilitation at UCSD’s Center for Psychedelic Research. Dr. Castellanos’ prime focus is improving function using an individualized approach. He is particularly interested in neuromodulation at various levels including spinal cord stimulation and peripheral nerve stimulation, interventional spine procedures, radiofrequency neurotomy, ultrasound-guided and fluoroscopically-guided procedures, and regenerative medicine such as platelet-rich plasma, stem cells, and Tenex (minimally invasive technology for treatment of chronic pain).

PhD candidate at the Centre for Psychedelic Research in Imperial College London's Division of Brain Science. He is a highly specialised pain physical therapist at The Pain Management Centre, Imperial College Healthcare NHS Foundation Trust. His research focus is neuropsychopharmacology of serotonergic psychedelics in chronic pain populations and other potential therapeutic applications. His clinical interests lie in the interface between physical and mental health, and he is a proponent of person-centred psychotherapeutically informed healthcare for physical health conditions.

Devon was a former Garland firefighter and Navy Veteran. In December 2012, he experienced a motor vehicle accident that resulted in a spinal cord injury (SCI) at C4-5 level. While he has regained movement of his arms and hands, Devon has little to no use of his fingers. In 2022, Devon was a volunteer for a published case study conducted by researchers at UC San Diego regarding microdosing of psilocybin for neuropathic pain.

Dr. Damaj earned his Ph.D. in Neuropharmacology from the University of Paris XI and completed his post-doctoral training with Dr. Billy R. Martin at VCU. The major emphasis of Dr. Damaj’s research is focused on the understanding the pharmacology and the role of neuronal nicotinic and neuroinflammatory mechanisms in CNS function and behavior (addiction, pain and neuropathy) using newly pharmacological tools and various mouse genetic approaches.

Director of facilitation for psychedelic therapy at UCSF, a mentor at the Center for Psychedelic Therapies and Research at CIIS, and faculty at the certificate for psychedelic therapy at the CAMP (UFRN) and Instituto Alma Viva in Brazil. A practicing psychotherapist for over 25 years, Gisele is specialized in the treatment of trauma, using an integrative approach rooted in Somatic, Humanistic-Existential and Transpersonal psychologies. She is dedicated to diversity and inclusion in her clinical, academic and research engagements. 

John is an ardent supporter of drug policy reform and believes the growing acceptance of psychedelics and psychedelic therapy marks a paradigm shift in the treatment of mental health. John was aware of the healing powers of psilocybin and other psychedelics but was truly blown away by a personal story from a patient in 2021. Since then, John has been focused on doing whatever possible to support the legalization of psychedelic therapy and to help change public perception towards it. He is honoured and privileged to support TheraPsil’s patients alongside such a professional and dedicated team.

Founder & CEO of Mountain Made Products, started growing his own mushrooms after they were credited with saving his life following a major traumatic brain injury (TBI) from a snowmobile accident. Despite the challenges of learning to walk and talk again, he defied conventional recovery expectations, thanks in part to his consumption of a blend of psychedelics prior to the accident.

Dr. Boris Heifets is a neuroanesthesiologist and Associate Professor in the Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University. He directs both clinical and basic neuroscience research programs, bridging neuroscience, psychiatry and anesthesiology. His research is focused on deconstructing the neural mechanisms involved in an emerging class of rapid-acting psychiatric therapies, like ketamine, MDMA and psilocybin. His group’s work is leading to new insights into the therapeutic potential of non-ordinary states of consciousness.

Dr. King completed residency in psychiatry at MGH/McLean followed by a fellowship in Consult-Liaison (CL) Psychiatry at MGH and a research fellowship at the MGH Cardiac Psychiatry Research Program. His areas of research include optimization of therapy paradigms within psychedelic research as well as the use of psychedelic-assisted therapies in disorders at the mind-body interface. Dr. King is currently the Principal Investigator in a pilot study exploring the feasibility of psilocybin-assisted therapy for irritable bowel syndrome, Co-PI for a collaboration with Fireside Project, a national psychedelic harm reduction organization, and is the study psychiatrist for a neuroimaging study examining the effects of MDMA-assisted therapy for fibromyalgia. 

Global Measurement & Insights Lead, Amazon. Lauren was a competitive athlete before undergoing multiple foot and Achilles surgeries that led to Complex Regional Pain Syndrome (CRPS), formally diagnosed in 2018. After years of immobility, disability leave, and failed interventions—including a spinal cord implant and various therapies—she discovered psilocybin microdosing. Within days, her mobility and quality of life improved significantly. Today, she walks independently without assistive devices, offering a powerful patient perspective on innovation and resilience in chronic pain care.

I work as a professor in psychopharmacology at Maastricht University, Netherlands. My research combines methods from psychopharmacology, forensic toxicology and cognitive neuroscience to determine drug induced changes in human performance. I focus on the impact of different substances of (ab)use, including cannabis, stimulants, opioids, novel psychoactive substances and psychedelics on neuronal networks and human cognition. This work bears relevance in the context of drug development and therapeutics and in legal settings when evaluating the impact of drug exposure on human function.

Sixth-year PhD candidate investigating the impact of psychedelics on cortical computations underlying persistent fear and pain in the Corder Lab at the University of Pennsylvania. Sophie's work has been published in Nature Neuroscience and was awarded an F31 training grant from the National Institute of Neurological Disorders and Stroke. She previously studied the molecular, cellular, and behavioral interplay of opioid and cannabinoid neural circuitry at Weill Cornell and the Icahn School of Medicine. In 2026, she will join the laboratory of Dr. Maria Geffen at UPenn to study the effect of psilocybin on auditory predictive processing in mouse models of autism spectrum disorder. 

Robin Sandell is a Research Associate at the Raj Lab at the University of California, San Francisco (UCSF), where she conducts mathematical modeling of neurodegenerative diseases, with a particular focus on biophysical models of pathological protein spread in Alzheimer’s. Her research interests extend beyond neurodegeneration to include the study of consciousness, neurological injuries, and therapeutic use of psychedelics.

Dr. Schindler is Medical Director of the Headache Center of Excellence at Veterans Affairs (VA) Connecticut Healthcare System and Assistant Professor of Neurology at Yale School of Medicine. Among her efforts to optimize headache diagnosis and management, she has worked to expand headache care to Veterans and educate practitioners nationally within VA. Her clinical focus is in cluster headache and other trigeminal autonomic cephalalgias. She executed the first controlled trial investigating the effects of psilocybin in cluster headache (and other headache disorders).

Dr. Tess Veuthey (MD/PhD) is a neurologist and pain physician whose work integrates neuromodulation and psychedelic therapies to develop safe, effective treatments for chronic pain and neuropsychiatric conditions—both within traditional medical settings and in broader community contexts. Her research spans systems neuroscience, chronic pain, psychedelics, and treatment access. She is currently leading a clinical trial recruiting patients with implanted brain monitoring devices to study how psilocybin alters the neural signatures of chronic pain. Beyond the lab and clinic, she volunteers with psychedelic support services at local and national events, including through the Zendo Project.

Clinical Psychology with an emphasis in Depth Psychology from Pacifica Graduate Institute. Sierra has worked with patients and research participants in the field of psychedelic medicine. Sierra supports patients with traumatic brain injuries, concussions, post-traumatic stress disorder, chronic illnesses, and other mental health conditions using the modalities of psychotherapy, EMDR and KAP.  For her doctoral research, Sierra pioneered a small, mixed-methods study using the Oregon Psilocybin Services model for women with fibromyalgia to undergo treatment with psilocybin.  

Josh Woolley is a psychiatrist and neuroscientist dedicated to developing and testing novel pharmacological treatments for individuals with mental illness. His earlier work explored the role of oxytocin in mental health, and his current research centers on psychoplastogens and related compounds in the treatment of psychiatric conditions such as depression, PTSD, and substance use disorders. His team has designed and implemented multiple clinical trials, including studies of MDMA-, psilocybin-, and psilocin-assisted therapies across diverse populations. He has actively engaged in addressing key challenges in psychedelic science, with a particular emphasis on improving clinical trial design to ensure rigorous and ethical evaluation of these novel interventions.

Dr. Steven Zeiler received his medical and doctor of philosophy degrees from the University of Colorado. He completed a one-year internal medicine internship at the University of Colorado prior to coming to Johns Hopkins for his residency training in Neurology and fellowship training in Vascular Neurology. As a stroke provider, Steve has first-hand knowledge of stroke, stroke treatment, and stroke recovery, all of which shape his laboratory research. Steve’s laboratory uses cutting-edge molecular, genetic, and behavioral techniques in animals with translational investigations in humans.